MorphoSys | Jotup

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on:

星期三, 三月 15, 2023

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

Key Points:

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.
MorphoSys presented at ASH 2022 results from analyses of the ongoing MANIFEST study in patients with myelofibrosis.
Total revenues for the fourth quarter 2022 were € 81.6 million compared to € 52.9 million for the same period in 2021.
This increase resulted mainly from higher revenues from the global licensing agreement with Novartis executed in the fourth quarter 2022.

EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023

Retrieved on:

星期六, 三月 11, 2023

EDT, Webcast, Conference, Management, CET, Q&A, MorphoSys, GMT, FSE, Cryptocurrency, Video game

Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023

Key Points:

Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
The issuer is solely responsible for the content of this announcement.
Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
MorphoSys' Management team will host a conference call and webcast on March 16, 2023 at 01:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present the results for the financial year 2022 and provide an outlook for 2023.
The conference call will start with a presentation by the Management team followed by a Q&A session.

EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

Retrieved on:

星期四, 三月 2, 2023

Research, Cancer, FSE, Investment, Workforce, Science, Patient, MorphoSys, Pharmaceutical industry, Ruxolitinib

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.

Key Points:

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure.
While the data from these pre-clinical programs are promising, MorphoSys would need to make substantial investments to bring these programs into the clinic.
As a result, MorphoSys will reduce its workforce at the company’s headquarters in Planegg, Germany, by approximately 17%.
The company will focus its remaining research work on translational research and technical development support for its mid- to late-stage clinical programs.

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on:

星期四, 二月 23, 2023

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022

Key Points:

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2022
Cash, cash equivalents, receivables and marketable debt securities totaled $613.5 million as of December 31, 2022, compared to $664.1 million on December 31, 2021.
Total revenue for the fourth quarter ended December 31, 2022 was $21.6 million compared to $154.0 million for the same period in 2021.
General and administrative (G&A) expenses for the fourth quarter ended December 31, 2022 were $12.8 million compared to $11.4 million for the same period in 2021.
ET (1:30 p.m. PT) to discuss the full year 2022 financial results and provide a corporate update.

EQS-News: iOmx Therapeutics appoints Dr. Christine Rothe as new Chief Development Officer

Retrieved on:

星期四, 二月 23, 2023

Apollon, Therapy, Immunotherapy, Cell biology, Cancer, University, CDO, Drug discovery, Research, Patient, Anticalin, Doctor of Philosophy, University of Regensburg, MorphoSys, Pharmaceutical industry

Martinsried / Munich, Germany, 23 February 2023 - iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Christine Rothe as Chief Development Officer.

Key Points:

Martinsried / Munich, Germany, 23 February 2023 - iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Christine Rothe as Chief Development Officer.
Dr. Rothe brings over 25 years of biopharma industry experience in research and drug discovery in various disease areas.
“I am delighted to have Christine join the iOmx team and lead our drug discovery and development activities.
I look forward to adding scientific knowledge and leadership experience to complement and further strengthen iOmx’ R&D capacity.”
Dr. Christine Rothe joins iOmx Therapeutics from Pieris Pharmaceuticals, where she served as VP Early-Stage Project Leadership & Data Science.

Vir Biotechnology Appoints Sung Lee as Chief Financial Officer

Retrieved on:

星期四, 二月 16, 2023

CFO, MorphoSys, Infection, Retirement, Acquisition, Patient, University, University of California, Irvine academics, Culture, Gilead Sciences, Dae Sung Lee, Economics, Growth, COVID-19, Sung, Management

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023. The appointment follows the resignation of Howard Horn, who will leave the Company after a brief transition period.

Key Points:

– Howard Horn departing to pursue next chapter; will remain in an advisory role through a brief transition period –
SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023.
“We are delighted to welcome Sung to Vir’s executive leadership team.
His exceptional track record of driving financial performance, scaling global operations, leading large teams and communicating with investors around the world will be critical to the next phase of Vir’s growth,” said George Scangos, Ph.D., Vir’s Chief Executive Officer.
“In addition to his impressive business and financial acumen, Sung brings a visionary mindset to the role that will be a great asset to the Company.

Paroxysmal Nocturnal Hemoglobinuria Market to Climb Moderately at a CAGR of 7.6% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on:

星期一, 一月 23, 2023

LAS VEGAS, Jan. 23, 2023 /PRNewswire/ -- DelveInsight's Paroxysmal Nocturnal Hemoglobinuria Market Insights report includes a comprehensive understanding of current treatment practices, paroxysmal nocturnal hemoglobinuria emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points:

In December 2022, Novartis released the efficacy and adverse event data from the phase III APPLY-PNH trial in paroxysmal nocturnal hemoglobinuria.
In September 2022, efficacy and safety data from a phase III trial in paroxysmal nocturnal hemoglobinuria were released by Alexion.
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological disorder characterized by intravascular hemolysis, hemoglobinuria, hemolysis, and venous thrombosis.
To know more about paroxysmal nocturnal hemoglobinuria treatment guidelines, visit @ Paroxysmal Nocturnal Hemoglobinuria Management

EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Retrieved on:

星期日, 一月 22, 2023

SG, FSE, Patient, Medicine, NCCN, B-cell lymphoma, Royalty Pharma, Life insurance, Security (finance), Bank, Assurance services, Bookkeeping, Clothing, Music, Tafasitamab, Incyte, MorphoSys

MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Key Points:

MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
The issuer is solely responsible for the content of this announcement.
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today reported preliminary Monjuvi® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023.
Preliminary Monjuvi (tafasitamab-cxix) U.S. net product sales are US$ 25.3 million (€ 24.0 million) for the fourth quarter and US$ 89.4 million (€ 84.9 million) for the full year of 2022.
For the full year of 2023, MorphoSys expects Monjuvi U.S. net product sales in the range of US$ 80 to 95 million.

EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023

Retrieved on:

星期日, 一月 22, 2023

Constellation, Cancer, Executive Committee, Ruxolitinib, Hope, CFO, FSE, Financial Oversight and Management Board for Puerto Rico, Supervisory board, Acquisition, Growth, Pleasure, Popular Executive Committee of Valencia, Sung, Environment, Management, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Sung Lee, the company’s Chief Financial Officer (CFO) and Management Board member, has decided to leave MorphoSys to move back to California for personal reasons.

Key Points:

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Sung Lee, the company’s Chief Financial Officer (CFO) and Management Board member, has decided to leave MorphoSys to move back to California for personal reasons.
“On behalf of the entire Supervisory Board, I want to thank Sung for his contributions to the success of MorphoSys.
He also established trusted relationships with our investors, the Executive Committee and Supervisory Board,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
“It’s been a pleasure to work with Sung and the entire MorphoSys team wishes him well.”
“The last two years have been an exciting time at MorphoSys as we have sharpened the company’s strategy and accelerated our ambition to become a leader in hematology-oncology,” said Sung Lee, Chief Financial Officer of MorphoSys.

EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

Retrieved on:

星期日, 一月 22, 2023

Patient, Standard of care, Webcast, BET, FSE, Conference, MorphoSys, Ruxolitinib, Pharmaceutical industry

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis – are expected to be available in early 2024.

Key Points:

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis – are expected to be available in early 2024.
The company previously communicated that these data were expected in the first half of 2024.
“For patients with myelofibrosis, depth and durability of responses are limited with current first-line therapy.
The latest Phase 2 data suggest pelabresib may have the potential to enhance the standard of care, reaffirming our confidence in the Phase 3 MANIFEST-2 study,” said Jean-Paul Kress.